Status: Recruiting
Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients
The study is a multi-centre, Open-label, Randomized Controlled, 1:1 trial comparing Prasugrel-based short DAPT (30-45 days) followed by Prasugrel monotherapy versus standard DAPT regimen in STEMI patients in terms of safety and efficacy endpoints. In the subgroup of STEMI patients with MVD, a sub-randomization will allow a comparison between a complete revascularization OCT-guided versus complete revascularization angiography-guided stent in terms of efficacy and safety endpoints.
Participants needed: 1,656
Trial details
Phase: Phase 4Biological sex: AllType: InterventionalSponsor: Research Maatschap Cardiologen Rotterdam ZuidUpdated: Jul 2, 2026Locations: 27
Eligibility criteria
ST segment elevation ≥2 contiguous ECG leads [+6]
Patients on oral anticoagulation [+14]